| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality?
|
Antonarakis, Emmanuel S
|
|
|
19 |
7 |
p. 860-861
|
artikel
|
| 2 |
Addendum to Lancet Oncol 2005; 6: 751–56
|
|
|
|
19 |
7 |
p. e335
|
artikel
|
| 3 |
Addition of mitoxantrone and prednisone to ADT
|
Gourd, Elizabeth
|
|
|
19 |
7 |
p. e336
|
artikel
|
| 4 |
Adjuvant therapy in resectable gastric cancer—the CRITICS trial
|
Lohr, Frank
|
|
|
19 |
7 |
p. e329
|
artikel
|
| 5 |
Adjuvant therapy in resectable gastric cancer—the CRITICS trial
|
Patel, Amol
|
|
|
19 |
7 |
p. e328
|
artikel
|
| 6 |
Adjuvant therapy in resectable gastric cancer—the CRITICS trial
|
Wang, Jingwen
|
|
|
19 |
7 |
p. e330
|
artikel
|
| 7 |
Adjuvant therapy in resectable gastric cancer—the CRITICS trial – Authors' reply
|
Cats, Annemieke
|
|
|
19 |
7 |
p. e331
|
artikel
|
| 8 |
2018 ASCO Annual Meeting
|
Gourd, Katherine
|
|
|
19 |
7 |
p. 865-866
|
artikel
|
| 9 |
Building independence in health care and a partnership between nations
|
Atrash, Fadi
|
|
|
19 |
7 |
p. 869-870
|
artikel
|
| 10 |
Cancer care in the Palestinian territories
|
Halahleh, Khalid
|
|
|
19 |
7 |
p. e359-e364
|
artikel
|
| 11 |
Cancer screening in the homeless population
|
Asgary, Ramin
|
|
|
19 |
7 |
p. e344-e350
|
artikel
|
| 12 |
Can Google help us fight cancer?
|
Wehner, Mackenzie R
|
|
|
19 |
7 |
p. 867
|
artikel
|
| 13 |
Chlamydia infection and ovarian cancer risk
|
Das, Manjulika
|
|
|
19 |
7 |
p. e338
|
artikel
|
| 14 |
Concurrent chemotherapy improves outcomes in HNSCC
|
Gourd, Elizabeth
|
|
|
19 |
7 |
p. e343
|
artikel
|
| 15 |
Correction to Lancet Oncol 2017; 18: 1061–75
|
|
|
|
19 |
7 |
p. e335
|
artikel
|
| 16 |
Correction to Lancet Oncol 2018; 19: 51–64
|
|
|
|
19 |
7 |
p. e335
|
artikel
|
| 17 |
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study
|
Noordman, Bo Jan
|
|
|
19 |
7 |
p. 965-974
|
artikel
|
| 18 |
Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis
|
Psallidas, Ioannis
|
|
|
19 |
7 |
p. 930-939
|
artikel
|
| 19 |
Diet, cancer, and NCD prevention
|
Marmot, Michael
|
|
|
19 |
7 |
p. 863-864
|
artikel
|
| 20 |
Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial
|
von Minckwitz, Gunter
|
|
|
19 |
7 |
p. 987-998
|
artikel
|
| 21 |
EMA restricts use of anti-PD-1 drugs for bladder cancer
|
Gourd, Elizabeth
|
|
|
19 |
7 |
p. e341
|
artikel
|
| 22 |
FLT3 inhibitors for relapsed or refractory acute myeloid leukaemia
|
Stein, Eytan M
|
|
|
19 |
7 |
p. 849-850
|
artikel
|
| 23 |
Gastrointestinal cancer risk in cystic fibrosis: more exploration is needed
|
Yao, Li
|
|
|
19 |
7 |
p. e332
|
artikel
|
| 24 |
Gastrointestinal cancer risk in cystic fibrosis: more exploration is needed – Authors' reply
|
Yamada, Akihiro
|
|
|
19 |
7 |
p. e333
|
artikel
|
| 25 |
How economic sanctions compromise cancer care in Iran
|
Aloosh, Mehdi
|
|
|
19 |
7 |
p. e334
|
artikel
|
| 26 |
Immunotherapy: hype and hope
|
The Lancet Oncology,
|
|
|
19 |
7 |
p. 845
|
artikel
|
| 27 |
Is there room for another HER2-targeting drug?
|
Gianni, Luca
|
|
|
19 |
7 |
p. 847-849
|
artikel
|
| 28 |
Lung cancer incidence higher in US women than men
|
Gourd, Elizabeth
|
|
|
19 |
7 |
p. e339
|
artikel
|
| 29 |
Lung transplantation for non-small cell lung cancer and multifocal bronchioalveolar cell carcinoma
|
Glanville, Allan R
|
|
|
19 |
7 |
p. e351-e358
|
artikel
|
| 30 |
Machine learning model in melanoma
|
Burki, Talha Khan
|
|
|
19 |
7 |
p. e340
|
artikel
|
| 31 |
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial
|
Dreno, Brigitte
|
|
|
19 |
7 |
p. 916-929
|
artikel
|
| 32 |
Malignant pleural effusions: will PROMISE make its name true?
|
Baas, Paul
|
|
|
19 |
7 |
p. 853-855
|
artikel
|
| 33 |
Miracle mineral or mesothelioma: cancer and asbestos in the USA
|
Lucas, Catherine
|
|
|
19 |
7 |
p. 868
|
artikel
|
| 34 |
More convenient proteasome inhibition for improved outcomes
|
Auner, Holger W
|
|
|
19 |
7 |
p. 856-858
|
artikel
|
| 35 |
Negative but not futile: MAGE-A3 immunotherapeutic for melanoma
|
Daud, Adil I
|
|
|
19 |
7 |
p. 852-853
|
artikel
|
| 36 |
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
|
Clarke, Noel
|
|
|
19 |
7 |
p. 975-986
|
artikel
|
| 37 |
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
|
Moreau, Philippe
|
|
|
19 |
7 |
p. 953-964
|
artikel
|
| 38 |
Oncogenic osteomalacia: diagnosis, localisation, and cure
|
Wan, Elizabeth
|
|
|
19 |
7 |
p. e365
|
artikel
|
| 39 |
Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial
|
Zhu, Hong-Hu
|
|
|
19 |
7 |
p. 871-879
|
artikel
|
| 40 |
Organ-preserving approaches in oesophageal cancer
|
Fitzgerald, Rebecca C
|
|
|
19 |
7 |
p. 858-859
|
artikel
|
| 41 |
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|
Zhu, Andrew X
|
|
|
19 |
7 |
p. 940-952
|
artikel
|
| 42 |
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
|
Cortes, Jorge
|
|
|
19 |
7 |
p. 889-903
|
artikel
|
| 43 |
Responses to carboplatin in BRCA1/2-mutated breast cancer
|
Burki, Talha Khan
|
|
|
19 |
7 |
p. e337
|
artikel
|
| 44 |
Ribociclib in premenopausal women with advanced breast cancer
|
Foukakis, Theodoros
|
|
|
19 |
7 |
p. 850-852
|
artikel
|
| 45 |
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|
Tripathy, Debu
|
|
|
19 |
7 |
p. 904-915
|
artikel
|
| 46 |
Shaping the landscape of immune oncology in hepatocellular carcinoma
|
Personeni, Nicola
|
|
|
19 |
7 |
p. 855-856
|
artikel
|
| 47 |
The LILAC trial and the blooming of anticancer biosimilars
|
Martin, Miguel
|
|
|
19 |
7 |
p. 861-863
|
artikel
|
| 48 |
Towards home-based treatment for acute promyelocytic leukaemia, with caution
|
Lo-Coco, Francesco
|
|
|
19 |
7 |
p. 846-847
|
artikel
|
| 49 |
Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study
|
Murthy, Rashmi
|
|
|
19 |
7 |
p. 880-888
|
artikel
|
| 50 |
Variations in breast cancer treatment and outcomes
|
Burki, Talha Khan
|
|
|
19 |
7 |
p. e342
|
artikel
|
Tijdschrift beschrijving